Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Accept all cookies Reject all non-essential cookies Find out more

Project funding for personalised childhood cancer treatments

MRC MHU Paediatrics

Funding from the Azaylia Foundation will support the Scientific Advances for Infant Leukaemia (SAIL) programme.

An adult holds a baby's hand in theirs. © Hu Chen/Unsplash

Yesterday it was announced that the Azaylia Foundation have donated £101,850 to fund the Scientific Advances for Infant Leukaemia (SAIL) programme, a UK-wide collaboration between the University of Oxford's Department of Paediatrics and Great Ormond Street Hospital.

The programme prioritises the development of treatments tailored to childhood cancers. Researchers in the programme, including the Childhood Leukaemia Research Group from the MRC WIMM and MRC MHU, aim to create a roadmap for all types of leukaemia, and improve prognosis for patients with cancers such as acute lymphoblastic leukaemia (ALL).

Tell us your news

Do you have a new publication? Received an award? Contact us to feature your story.

Similar stories

T cell Immunotherapy animation launched

A new animation explores work by the Chakraverty Group, Vyas Group, and Professor Borrow from the Jenner Institute.

Irene Roberts delivers Ham-Wasserman Lecture

Presented at the American Society of Hematology Annual Meeting, the award and lectureship recognises individuals from outside the United States who have made significant contributions to Haematology.

Asger Jakobsen receives ASH-BSH Abstract Achievement Award

Dr Jakobsen, a Clinical Research Fellow and DPhil student from the Vyas Group has received the award from the American Society of Hematology and the British Society of Haematology.

Researchers make miniature ‘bone marrows in a dish’ to improve anti-cancer treatments

Nucleome Therapeutics raises oversubscribed £37.5 million Series A financing

The biotechnology company builds upon research conducted by Professor Jim Hughes and Prof. James Davies at the MRC Weatherall Institute of Molecular Medicine, and combines 3D genome technology and machine learning to decode the dark matter of the human genome.

KJ Patel appointed new Chief Scientist of CRUK

Alongside his new role at Cancer Research UK, Prof. Patel will continue as the Director of both the MRC Weatherall Institute for Molecular Medicine (MRC WIMM) and the MRC Molecular Haematology Unit (MRC MHU).